This was the stock's third consecutive day of gains.

A driver has serious injuries following a rollover crash on Gilead Street in Hebron Monday, state police said. State police ...

Deutsche Bank upgraded Gilead Sciences (NASDAQ:GILD) on Tuesday, citing the antiviral developer’s HIV treatment franchise, ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

CompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

Assembly Bio said that it plans to advance ABI-1179 directly into the Phase 1b portion of the study, which will include ...

Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...

Bernstein raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes Gilead ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...